𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Circulating levels of insulin-like growth factor-I and risk of ovarian cancer

✍ Scribed by Annekatrin Lukanova; Eva Lundin; Paolo Toniolo; Andrea Micheli; Arslan Akhmedkhanov; Sabina Rinaldi; Paola Muti; Per Lenner; Carine Biessy; Vittorio Krogh; Anne Zeleniuch-Jacquotte; Franco Berrino; Göran Hallmans; Elio Riboli; Rudolf Kaaks

Publisher
John Wiley and Sons
Year
2002
Tongue
French
Weight
91 KB
Volume
101
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Insulin‐like growth factor (IGF)‐I, a mitogenic and anti‐apoptotic peptide, has been implicated in the development of several cancers. We hypothesized that high circulating IGF‐I concentrations may be associated with an increased risk of ovarian cancer. A case–control study was nested within 3 prospective cohorts in New York (USA), Umeå (Sweden) and Milan (Italy). One hundred thirty‐two women with primary invasive epithelial ovarian cancer diagnosed at least 1 year after blood donation were case subjects. For each case, 2 control subjects were selected, matching the case subject on cohort, menopausal status, age and date of recruitment (n = 263). Only women who did not use exogenous hormones at blood donation were included in the study. There was no association between IGF‐I concentrations and ovarian cancer risk in the study group as a whole. In analyses restricted to subjects who had developed ovarian cancer at a young age (<55), circulating IGF‐I was directly and strongly associated with ovarian cancer risk (OR = 4.97; 95% CI = 1.22–20.2 for the top vs. the bottom IGF‐I tertile after adjustment for parity, BMI categories and smoking). There was no significant association of IGF binding protein‐3 with ovarian cancer risk. We found a strong direct relationship between circulating IGF‐I levels and risk of developing ovarian cancer before age 55. Additional, larger studies of this association are needed to provide more precise estimates of effect. © 2002 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Premenopausal levels of circulating insu
Premenopausal levels of circulating insulin-like growth factor I and the risk of postmenopausal breast cancer
✍ Dana E. Rollison; Craig J. Newschaffer; Yuzhen Tao; Michael Pollak; Kathy J. Hel 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 94 KB 👁 1 views

## Abstract Increased levels of insulin‐like growth factor I (IGF‐I) may directly stimulate breast cell proliferation and promote growth and survival of transformed cells. Higher levels of IGF‐I have been associated with increased risk of premenopausal breast cancer but not postmenopausal breast ca

Free insulin-like growth factor-I and br
Free insulin-like growth factor-I and breast cancer risk
✍ Benjamin D.L. Li; M. Javad Khosravi; Hans J. Berkel; Anastasia Diamandi; Mark A. 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 56 KB 👁 2 views

Insulin-like growth factor-I (IGF-I) has mitogenic and antiapoptotic effects on breast cancer cells. Epidemiologic studies have shown that high plasma levels of IGF-I and low levels of IGF binding protein (BP)-3 are associated with increased risk of breast cancer in premenopausal women. The actions

Serum insulin-like growth factor-I, insu
Serum insulin-like growth factor-I, insulin-like growth factor binding protein-3, and the risk of pancreatic cancer death
✍ Yingsong Lin; Akiko Tamakoshi; Shogo Kikuchi; Kiyoko Yagyu; Yuki Obata; Teruo Is 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 75 KB 👁 1 views

## Abstract Recent epidemiological studies have shown that high serum levels of insulin‐like growth factor‐I (IGF‐I) are associated with an increased risk of lung, colon, breast and prostate cancer. Since very few studies have addressed the role of serum levels of IGF‐I in the development of pancre

Circulating levels of insulin-like growt
Circulating levels of insulin-like growth factor I, its binding proteins -1,-2, -3, C-peptide and risk of postmenopausal breast cancer
✍ Lital Keinan-Boker; H. Bas Bueno de Mesquita; Rudolf Kaaks; Carla H. van Gils; P 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 French ⚖ 85 KB 👁 1 views

## Abstract Higher levels of circulating Insulin‐like Growth Factor (IGF)‐I may be associated with higher risks for premenopausal breast cancer. We investigate the associations between circulating levels of IGF‐I, its binding proteins (IGFBPs) ‐1, ‐2, ‐3, C‐peptide and postmenopausal breast cancer.